lansoprazole has been researched along with Gastric Fistula in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Gastric Fistula: Abnormal passage communicating with the STOMACH.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uchiyama, K | 1 |
| Wakatsuki, D | 1 |
| Kakinoki, B | 1 |
| Takeuchi, Y | 1 |
| Araki, T | 1 |
| Morinaka, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for lansoprazole and Gastric Fistula
| Article | Year |
|---|---|
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carba | 1999 |
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carba | 1999 |
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carba | 1999 |
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carba | 1999 |